The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette-Guerin

被引：12

作者：

Hegazy, Raafat ^{[1
]}

Kamel, Mostafa ^{[3
]}

Salem, Emad A. ^{[3
]}

Salem, Neveen A. ^{[6
]}

Fawzy, Amr ^{[3
]}

Sakr, Ahmed ^{[3
]}

El-Farargy, Ola ^{[4
]}

Nawar, Nashwa ^{[5
]}

El-Atar, Ahmed ^{[5
]}

Shahin, Ashraf M. S. ^{[3
]}

Hegazy, Abdelmonem ^{[2
]}

机构：

[1] Zagazig Univ, Fac Med, Dept Pathol, Cairo, Egypt

[2] Zagazig Univ, Fac Med, Dept Med Oncol, Cairo, Egypt

[3] Zagazig Univ, Fac Med, Dept Anat, Cairo, Egypt

[4] Zagazig Univ, Fac Med, Dept Urol, Cairo, Egypt

[5] Zagazig Univ, Fac Med, Dept Radiotherapy, Cairo, Egypt

[6] Natl Res Ctr, Cairo, Egypt

来源：

ARAB JOURNAL OF UROLOGY | 2015年 / 13卷 / 03期

关键词：

Bladder cancer; P53; P63; Her2; BCG;

D O I：

10.1016/j.aju.2015.05.001

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To investigate whether the immunohistochemical expression of p53, p63 and her2/neu is correlated with the prognosis of tumour recurrence and progression in patients with non-muscle invasive (NMI) bladder cancer. Patients and methods: In all, 88 patients diagnosed with NMI transitional cell carcinoma of the bladder in a Urology Department from May 2009 to April 2014 were included in the study. Paraffin-embedded specimens were obtained by transurethral resection of the bladder tumours. Sections on haematoxylin and eosin-stained slides were examined histologically and tumour grade was classified according to the World Health Organisation system (2004) Mostofi classification. The sections were evaluated using p63, p53 and her2/neu immunohistochemical staining before and after immunotherapy with bacille Calmette-Guerin (BCG), and patients were followed up for 36 months in the Urology Department. Results: For tumour grade there was a significant relationship with the overexpression of p53 (P = 0.010), her2 (P = 0.025) and negativity of p63 (P = 0.025). There was no significant relationship between p53 or her2/neu overexpression and tumour stage. However, there was a significant correlation (P = 0.005) between p63 negativity and tumour stage. There was a significant relationship between p53 (P = 0.01), her2/neu (P = 0.025) overexpression and p63 negativity (P = 0.005) and tumour recurrence and progression. Conclusion: Patients with transitional cell carcinoma who are selected for BCG treatment should preferably be positively immunoreactive for p63, but negative for both p53 and her2/neu. These patients were less susceptible to recurrence and/or progression after BCG adjuvant therapy. Further studies are needed to investigate the relationship between these three markers and treatment with anti-her2/neu therapies. (C) 2015 Arab Association of Urology. Production and hosting by Elsevier B.V.

引用

页码：225 / 230

页数：6

共 31 条

[1]

Alexa A, 2010, ROM J MORPHOL EMBRYO, V51, P277

[2]

Cormio L, 2009, ANTICANCER RES, V29, P4201

[3]

Di Como CJ, 2002, CLIN CANCER RES, V8, P494

[4]

Eble JN, 2004, PATHOLOGY GENETICS T